Adma Biologics, Inc. Stock: price and insider trades · United States

ADMA Biologics, Inc. is a U.S.-listed biopharmaceutical company traded on the Nasdaq (NASDAQ: ADMA) in the United States, with core operations in New Jersey and Florida. For international investors, the name sits squarely in the Health & Pharma sector, more specifically in plasma-derived biologics and immune globulin therapies. ADMA describes itself as an end-to-end commercial biopharmaceutical company, meaning it participates across development, manufacturing, commercialization, and part of the supply chain for its own products. The company’s strategic niche is attractive: it focuses on specialized therapies for immunocompromised patients and other populations at risk for certain infectious diseases, rather than broad mass-market pharmaceuticals. Founded on June 24, 2004, ADMA has spent two decades building an integrated platform around plasma-based medicines.

ADMA’s approved commercial portfolio consists of three FDA-licensed products: ASCENIV, BIVIGAM, and NABI-HB. ASCENIV is the key growth engine and has recently driven the company’s revenue acceleration, supported by stronger physician adoption, broader payer access, and continued patient demand. BIVIGAM remains part of the core franchise, while NABI-HB provides additional exposure to hepatitis B immune globulin. Beyond the marketed portfolio, ADMA is also advancing SG-001, a preclinical pipeline program aimed at broader pneumococcal serotype coverage. While still early-stage, this program gives the company longer-dated optionality beyond its current commercial base.